Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-25T01:02:49.273Z Has data issue: false hasContentIssue false

Clinical Significance of Neutropenia in Patients With Human Immunodeficiency Virus Infection

Published online by Cambridge University Press:  21 June 2016

Bruce F. Farber*
Affiliation:
Departments of Medicine and Biostatistics, North Shore University Hospital, Manhasset, New York Cornell University Medical College, New York, New York
Martin Lesser
Affiliation:
Departments of Medicine and Biostatistics, North Shore University Hospital, Manhasset, New York Cornell University Medical College, New York, New York
Mark H. Kaplan
Affiliation:
Departments of Medicine and Biostatistics, North Shore University Hospital, Manhasset, New York Cornell University Medical College, New York, New York
Jeanine Woltmann
Affiliation:
Departments of Medicine and Biostatistics, North Shore University Hospital, Manhasset, New York
Barbara Napolitano
Affiliation:
Departments of Medicine and Biostatistics, North Shore University Hospital, Manhasset, New York
Donna Armellino
Affiliation:
Departments of Medicine and Biostatistics, North Shore University Hospital, Manhasset, New York
*
Division of Infectious Disease and Immunology, North Shore University Hospital, 300 Community Drive, Manhasset, New York 11030

Abstract

Objective:

To determine the incidence of infection in human immunodeficiency virus (HIV)-infected patients during periods of neutropenia and non-neutropenia. To compare the infection rates in patients with HIV disease to those in a group hospitalized with neutropenia and hematologic malignancy.

Design:

Prospective observational study conducted between December 1985 and December 1987 at a university teaching hospital. Thirty patients with documented acquired immunodeficiency syndrome (AIDS) and absolute T-helper cells <200 mm/mm3. All patients had a period of non-neutropenia following a neutropenic period (neutrophils <1000 cells/mm3).

Results:

The rate of first infection during neutropenic and non-neutropenic periods for opportunistic infection and nonopportunistic infections were compared. There were no differences between infection rates for the two time periods for both types of infections. A subgroup of patient care days in which non-neutropenic days followed neutropenic days also was studied to eliminate selection bias. In this group, a comparison of infection rates also revealed no difference between neutropenic and non-neutropenic periods. An alternate analysis of the time until first infection during periods of neutropenia or non- neutropenia was done using the Kaplan-Meier product limit method. There was a longer infection-free period for the neutropenic group for opportunistic infections, but it was not statistically significant (p<.1). In addition, we compared HIV-infected patients with a group of 37 patients with neutropenia from hematologic malignancy. There was a significantly higher rate of all infections, particularly bacteremias (p<.001), in the group of patients with hematologic malignancies when compared with all subsets of patients with HIV disease.

Conclusion:

We conclude that patientswith HIV disease and modest neutropenia do not have an increased risk of bacterial infection. The incidence of all infections is significantly greater in patients with neutropenia secondary to hematologic malignancy, (Infect Control Hosp Epidemiol. 1991;12:429-434.)

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Zon, LI, Arkin, C, Groopman, JE. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol. 1987;66:251256.Google Scholar
2. Murphy, ME Metcalfe, P, Waters, AH, et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol. 1987;66:337340.Google Scholar
3. Castella, A, Cloxson, TS, Mildvan, D, et al. The bone marrow in AIDS. Am J Clin Pathol. 1984;84:425432.Google Scholar
4. Richman, DD, Fischl, MA. Grieco, MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;517:192196.Google Scholar
5. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR. 1987;36:15.Google Scholar
6. Kleinbaum, DG, Kupper, LL, Morganstern, H. Epidemiologic Research. Belmont, Calif: Lifetime Learning Publications; 1982.Google Scholar
7. Mantel, N, Ciminera, JL. Use of log rank scores in the analysis of litter-matched data on time to tumor appearance. Cancer Res. 1979;39:43084315.Google Scholar
8. Peto, R, Peto, J. Asymptomatically efficient rank invariant test procedures. Journal of the Royal Statistics Society. 1972;135:185206.Google Scholar
9. Rubin, R, Young, L, eds. Clinical Approach to Infections in the Compromised Host. New York, NY: Plenum Medical; 1988.Google Scholar
10. Whimbey, E, Gold, JWM, Polsky, B, et al. Bacteremia and fungemia in patients with the acquired immune deficiency syndrome. Ann Intern Med. 1986;104:511514.Google Scholar
11. Simberkoff, MS, El Sadr, W, Schiffman, G, Rahal, JJ Jr. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome with report of a pneumococcal failure. Am Rev Respir Dis. 1984;130:11741176.Google Scholar
12. Glatt, AE, Chirquin, K, Landesman, SA. Treatment of infections associated with human immunodeficiency virus. N Engl J Med. 1988;318:14391448.Google Scholar